[go: up one dir, main page]

WO2008100977A3 - Carbamates therapeutic release agents as amidase inhibitors - Google Patents

Carbamates therapeutic release agents as amidase inhibitors Download PDF

Info

Publication number
WO2008100977A3
WO2008100977A3 PCT/US2008/053785 US2008053785W WO2008100977A3 WO 2008100977 A3 WO2008100977 A3 WO 2008100977A3 US 2008053785 W US2008053785 W US 2008053785W WO 2008100977 A3 WO2008100977 A3 WO 2008100977A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamates
release agents
therapeutic release
inhibitors
faah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/053785
Other languages
French (fr)
Other versions
WO2008100977A2 (en
Inventor
Olivier Dasse
Jeff A Parrott
David Putman
Julia Adam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of WO2008100977A2 publication Critical patent/WO2008100977A2/en
Publication of WO2008100977A3 publication Critical patent/WO2008100977A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.
PCT/US2008/053785 2007-02-14 2008-02-13 Carbamates therapeutic release agents as amidase inhibitors Ceased WO2008100977A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88990907P 2007-02-14 2007-02-14
US60/889,909 2007-02-14
US94808207P 2007-07-05 2007-07-05
US60/948,082 2007-07-05

Publications (2)

Publication Number Publication Date
WO2008100977A2 WO2008100977A2 (en) 2008-08-21
WO2008100977A3 true WO2008100977A3 (en) 2008-12-18

Family

ID=39595757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/053785 Ceased WO2008100977A2 (en) 2007-02-14 2008-02-13 Carbamates therapeutic release agents as amidase inhibitors

Country Status (1)

Country Link
WO (1) WO2008100977A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103027909B (en) * 2011-11-28 2015-01-14 贵阳中医学院 Application of coumarins compounds and method for extracting coumarins compounds from winter daphne
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361581C2 (en) * 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Pharmaceutical composition possessing antidiabetic, hypolipidemic, hypoglycemic and cholesterol lowering action, way of its reception and ways of treatment of specified diseases
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
US9073879B2 (en) * 2010-04-22 2015-07-07 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of FAAH
JP6046034B2 (en) 2010-06-03 2016-12-14 ユナイテッド セラピューティクス コーポレイション Production of treprostinil
US8461393B2 (en) 2011-03-02 2013-06-11 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
ES2389070B1 (en) * 2011-03-24 2013-09-17 Universidad De La Laguna DERIVED FROM PRENILATED DIBENZOFURANIC POLYCETIDES AND THEIR APPLICATION FOR THE TREATMENT OF INFECTIOUS, PARASITIC DISEASES AND TUMORS.
CN103204838B (en) * 2012-01-13 2017-06-09 北京盛诺基医药科技有限公司 The synthesis of polyhydroxy Benzofurantone compound and its antitumor action
US20130266643A1 (en) * 2012-04-10 2013-10-10 Hpo Life Sciences, Inc. Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis
CN103374049B (en) * 2012-04-18 2016-04-06 昆药集团股份有限公司 One prepares 5,6, the method for 4 '-trihydroxyflavone-7-0-D-glucuronic acid
CN103374050B (en) * 2012-04-18 2015-09-23 昆明制药集团股份有限公司 One prepares 5,6, the method for 4 '-trihydroxyflavone-7-0-D-glucuronic acid
EP3732994B1 (en) 2013-02-08 2022-11-09 General Mills, Inc. Reduced sodium food products
US10568900B1 (en) 2013-03-15 2020-02-25 Suzanne Janine Paxton-Pierson Androgen effectors
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015265865C1 (en) 2014-05-28 2025-01-30 Universitat Bern Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN107108427A (en) 2014-10-20 2017-08-29 联合治疗学有限公司 For the synthesis for the intermediate for preparing prostacyclin derivatives
EP3303283B1 (en) * 2015-06-23 2021-04-21 National Institute Of Biological Sciences, Beijing Fto inhibitors
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
CN105147661B (en) * 2015-08-07 2017-12-08 上海中医药大学 Application of the macrotin in the medicine or food for preparing preventing and treating ulcerative colitis
CN106673984B (en) * 2015-11-11 2020-01-10 上海医药工业研究院 (E) -2, 4-dihydroxy-6-propenylbenzaldehyde, preparation method and use thereof
JP6600832B2 (en) * 2015-12-11 2019-11-06 小林 裕司 Methylated flavonol derivatives exhibiting fat adsorption
WO2017205939A1 (en) * 2016-06-03 2017-12-07 Indigo Ridge Pty Ltd Vitamin d formulations and therapeutic uses thereof
CN109937036A (en) * 2016-10-21 2019-06-25 赛威蒂斯株式会社 Pharmaceutical composition for the prevention or treatment of diabetes and/or hyperlipidemia comprising midodrine or a pharmaceutically acceptable salt thereof as an active ingredient
JP6814470B2 (en) * 2017-02-10 2021-01-20 国立大学法人 筑波大学 Morhinan derivative
MY172113A (en) 2017-07-05 2019-11-14 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US11407728B2 (en) 2017-09-20 2022-08-09 The Board Of Trustees Of The University Of Illinois Derivatives of EPA endocannabinoid epoxides as anti-inflammatory, anti-cancerous, anti-angiogenc and antiplatelet aggregation compounds
US11472787B2 (en) 2017-09-20 2022-10-18 The Board Of Trustees Of The University Of Illinois Docosahexaenoic acid endocannabinoid epoxide derivative compositions
CN110407741B (en) * 2018-04-26 2023-03-21 启元生物(杭州)有限公司 Anti-inflammatory compound and preparation and application thereof
AU2019343922B2 (en) 2018-09-18 2024-01-25 1Globe Biomedical Co., Ltd. Treatment for obesity
WO2020061232A1 (en) 2018-09-18 2020-03-26 1 Globe Biomedical Co., Ltd. Treatment for non-alcoholic fatty liver disease
CN109456268A (en) * 2018-11-08 2019-03-12 中国药科大学 The preparation of 3, the 4- dihydro-isoquinoline Alkaloid of C1 substitutions and its medical usage
CN109674807A (en) * 2019-01-18 2019-04-26 中国医学科学院阜外医院 A kind of CSE zymoexciter and its with CSE/H2Application in the relevant disease medicament of S system
KR102360675B1 (en) * 2019-05-16 2022-02-08 단국대학교 천안캠퍼스 산학협력단 Composition for Inhibiting Angiogenesis Using an Broussonetia kazinoki Extract Containing Broussonin
US11026896B2 (en) * 2019-06-18 2021-06-08 Dyve Biosciences, Inc. Transdermal penetrant formulations containing cannabidiol
CN110850019B (en) * 2019-11-29 2022-02-18 南京南医堂健康产业发展有限公司 Method for detecting fingerprint of Minggu Shuqing drink
WO2021243201A1 (en) * 2020-05-29 2021-12-02 The University Of Mississippi Topical compositions for treating peripheral neuropathic pain
WO2022020222A1 (en) * 2020-07-21 2022-01-27 Neuritek Ltd. Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders
CN111888350B (en) * 2020-09-03 2022-01-25 中国科学院华南植物园 Application of morin N in preparation of products for preventing and treating iron death related diseases
CN112156091A (en) * 2020-09-30 2021-01-01 中山大学附属第一医院 Application of hispidulin in preparation of medicine for treating and/or preventing cardiovascular diseases
CN112645913B (en) * 2020-12-28 2023-11-24 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) A kind of p-terphenyl compound and its preparation method and application
US20240366555A1 (en) * 2021-04-13 2024-11-07 Aliad Biopharma Selective mtorc2 inhibitor and uses thereof
CN113288879B (en) * 2021-05-25 2022-09-02 四川永诺生物科技有限公司 Preparation method of enteric-coated particles of carbasalate calcium
CN115554240B (en) * 2021-07-02 2023-09-15 福建中医药大学 A triptolide/glycyrrhetinic acid-carboxymethyl chitosan-thioketal-rhein micelle
CN113456626B (en) * 2021-08-16 2022-05-06 吉林大学 Xanthine oxidase inhibitor and screening method and application thereof
CN114989180B (en) * 2022-05-26 2024-06-04 广东海洋大学 Yang Shexiao compound derived from endophytic fungi of hibiscus, and preparation method and application thereof
CN116098912B (en) * 2023-02-24 2025-08-08 广西壮族自治区药用植物园 Combination of flavonoid glycosides for treating chronic obstructive pulmonary disease
CN116139072A (en) * 2023-04-07 2023-05-23 南京大学 Salvianolic acid A carbomer gel and application thereof
CN116251111A (en) * 2023-04-28 2023-06-13 天津大学 A composition for inhibiting α-glucosidase and its application
WO2025013019A1 (en) * 2023-07-07 2025-01-16 Kapil Bhimani Haemostatic agent formulation
CN117298098A (en) * 2023-11-15 2023-12-29 南通大学 Application of decursin in preparation of medicines for treating vascular dementia
CN117820265A (en) * 2023-12-29 2024-04-05 景洪宏臻农业科技有限公司 Boletus-like acid compound or derivative thereof, and preparation method and application thereof
CN118490678B (en) * 2024-05-29 2024-12-06 南通大学 Application of nuciferine in preparing medicine for preventing or treating nonalcoholic steatohepatitis
CN118750487B (en) * 2024-09-06 2024-11-19 深圳市利云德生物技术有限公司 Anti-gastric cancer pharmaceutical composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033422A2 (en) * 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033422A2 (en) * 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEGLEY ET AL: "Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, EXPERIMENTAL THERAPEUTICS, BALTIMORE, MD, vol. 313, no. 1, 1 January 2005 (2005-01-01), pages 352 - 358, XP002459348, ISSN: 0022-3565 *
GREENWALD R B: "Drug delivery systems: Anticancer prodrugs and their polymeric conjugates", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 7, no. 6, 6 June 1997 (1997-06-06), pages 601 - 609, XP002296827, ISSN: 1354-3776 *
HERTZOG D L: "Recent advances in the cannabinoids", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 14, no. 10, 1 January 2004 (2004-01-01), pages 1435 - 1452, XP002362228, ISSN: 1354-3776 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103027909B (en) * 2011-11-28 2015-01-14 贵阳中医学院 Application of coumarins compounds and method for extracting coumarins compounds from winter daphne
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses

Also Published As

Publication number Publication date
WO2008100977A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
WO2008100977A3 (en) Carbamates therapeutic release agents as amidase inhibitors
WO2008024139A3 (en) Inhibitors of fatty acid amide hydrolase
MX341110B (en) Faah inhibitors.
WO2008047229A3 (en) Biaryl ether urea compounds
WO2011123719A3 (en) Use of faah inhibitors for treating abdominal, visceral and pelvic pain
WO2008063300A3 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
WO2008021625A3 (en) Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2010074588A3 (en) Pharmaceutical compounds
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
PL1836179T3 (en) Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
GB0710455D0 (en) Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
IL198979A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
IL191819A0 (en) Inhibitors of fatty acid amide hydrolase
EP1954137A4 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
WO2008145842A3 (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
IL188438A (en) Pharmacologically active benzofused five-membered heterocycles, or pharmaceutically acceptable salts and esters thereof and pharmaceutical compositions containing them and their use as inhibitors of catechol-o-methyltransferase (comt) enzyme
TNSN07435A1 (en) Novel piperidine carboxylic acid amide derivatives
IL185457A0 (en) 5-phenyl-pentanoic acid derivatives as metrix metalloproteinase inhibitors for the treatment of asthma and other diseases
ZA200805473B (en) Inhibitors of fatty acid amide hydrolase
WO2012167133A3 (en) Inhibitors of anandamide transport and their therapeutic uses
WO2012145737A8 (en) Fatty acid amide hydrolase inhibitors for treating pain
BR112012019120A2 (en) solid form, pharmaceutical composition, method of preparing compound 1, method of treating a faah-mediated condition
WO2005110493A3 (en) Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08729708

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08729708

Country of ref document: EP

Kind code of ref document: A2